Company Profiles

driven by the PitchBook Platform

Thetis Pharmaceuticals

Description

Developer of pharmaceutical drugs. The company is focused on type 2 diabetes, and is working to advance its TP101, which is a new molecular entity that chemically combines metformin, the standard of care in type 2 diabetes, with the principal component from omega-3 polyunsaturated fatty acids. Its TP101 uniquely targets both glycemic and lipid control in diabetes patients and has the potential to address cardiovascular complications.

2011

Founded

PRIVATE

Status

Early Stage VC

Latest Deal Type

$4.11M

Latest Deal Amount

$12.4M

Total Amount Raised

7

Investors

Description

Developer of pharmaceutical drugs. The company is focused on type 2 diabetes, and is working to advance its TP101, which is a new molecular entity that chemically combines metformin, the standard of care in type 2 diabetes, with the principal component from omega-3 polyunsaturated fatty acids. Its TP101 uniquely targets both glycemic and lipid control in diabetes patients and has the potential to address cardiovascular complications.

Website:

www.thetispharma.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Pharmaceuticals
Drug Delivery

Primary Office

167 Old Post Road 2nd Floor Fairfield, CT 06890United States +1 (860) 213-1235
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Thetis Pharmaceuticals's full profile, request a free trial.

    Thetis Pharmaceuticals Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Thetis Pharmaceuticals Investors (7)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Connecticut InnovationsVenture CapitalMinority000 0000000 0000
    Individual InvestorAngel (individual)Minority000 0000000 0000
    Paul SilvaAngel (individual)Minority000 0000000 0000
    River Valley InvestorsAngel GroupMinority000 0000000 0000
    Stonehenge Capital CompanyPE/BuyoutMinority000 0000000 0000
    Connecticut Innovations Venture Capital
    Individual Investor Angel (individual)
    Paul Silva Angel (individual)
    River Valley Investors Angel Group
    Stonehenge Capital Company PE/Buyout

    Thetis Pharmaceuticals Executive Team (3)

    NameTitleBoard
    Seat
    Contact
    Info
    Frank Sciavolino Ph.DCo-Founder, President, Chief Scientific Officer and Board Member
    Gary MathiasCo-Founder, Chief Executive Officer, Chief Revenue Officer, Manager & Board Member
    Alexander Fleming MDChief Clinical and Regulatory Officer
    Frank Sciavolino Ph.D Co-Founder, President, Chief Scientific Officer and Board Member
    Gary Mathias Co-Founder, Chief Executive Officer, Chief Revenue Officer, Manager & Board Member
    Alexander Fleming MD Chief Clinical and Regulatory Officer

    Thetis Pharmaceuticals Board Members (5)

    NameRepresentingRoleSinceContact
    Info
    David WurzerConnecticut InnovationsExecutive Vice President & Chief Investment Officer000 0000
    Dennis WillsonSelfBoard Member000 0000
    Frank Sciavolino Ph.DThetis PharmaceuticalsCo-Founder, President, Chief Scientific Officer and Board Member000 0000
    Gary MathiasSelfCo-Founder, Chief Executive Officer, Chief Revenue Officer, Manager & Board Member000 0000
    Lillian MuConnecticut InnovationsSenior Investment Associate000 0000
    David Wurzer Executive Vice President & Chief Investment Officer Connecticut Innovations
    Dennis Willson Board Member Self
    Frank Sciavolino Ph.D Co-Founder, President, Chief Scientific Officer and Board Member Thetis Pharmaceuticals
    Gary Mathias Co-Founder, Chief Executive Officer, Chief Revenue Officer, Manager & Board Member Self
    Lillian Mu Senior Investment Associate Connecticut Innovations
    Request full access to PitchBook